ProCE Banner Activity

Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH

Slideset Download

In these unlocked downloadable slides, experts provide a review of therapeutic interventions for NAFLD/NASH including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.

Released: November 04, 2022

Expiration: November 03, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Faculty Disclosure

Primary Author

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Rohit Loomba, MD, MHSc

Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Director, MASLD Research Center
University of California, San Diego
San Diego, California

Rohit Loomba, MD, MHSc: consultant/advisor/speaker: 89Bio, Aardvark, Altimmune, Arrowhead, AstraZeneca, Cascade, Gilead, Glympse Bio, Inipharma, Intercept, Inventiva, Ionis, Janssen, Lilly, Lipidio, Madrigal, Merck, Neurobo, Novo Nordisk, Pfizer, Sagimet, Takeda, Terns, Viking; stock options: Sagimet Biosciences; research grants paid to institution: Arrowhead, Astrazeneca, Boehringer Ingelheim, Bristol Myers Squibb, Galectin, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Lilly, Madrigal, Merck, Novo Nordisk, Pfizer, Sonic Incytes, Terns; co-founder: LipoNexus.

Brent A. Neuschwander-Tetri, MD

Professor of Internal Medicine
Saint Louis University Liver Center
Division of Gastroenterology and Hepatology
Saint Louis University School of Medicine
St. Louis, Missouri